Maze Therapeutics CEO sells 34.5K shares
Maze Therapeutics’ CEO had 50,000 RSUs settle into common stock while associated trusts sold 34,501 shares under a Rule 10b5-1 plan.
Rhea-AI Filing Summary
Maze Therapeutics, Inc. (MAZE) reported that Chief Executive Officer and director Jason V. Coloma had 50,000 restricted stock units settle into 50,000 shares of common stock on September 1, 2026. On the same date, entities for which he and his spouse serve as co‑trustees sold a total of 34,501 shares of common stock at weighted average prices around $26.30 per share under a Rule 10b5-1 trading plan. Following these transactions, the trusts reported holdings of 223,355 and 18,151 shares, and Coloma held 50,000 shares directly from the RSU settlement.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
4 txns
Insider
Coloma Jason V
Role
Chief Executive Officer
Sold
34,501 shs ($907K)
Approx. gross sale proceeds
$907K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F6, F7, F8 | 50,000 | $0.00 | $0.00 |
| Sale | Common Stock F1, F2, F3 | 2,593 | $26.307 | $68K |
| Sale | Common Stock F1, F4, F5 | 31,908 | $26.2876 | $839K |
| Exercise | Common Stock | 50,000 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Units — 50,000 contracts (Direct);
Common Stock — 18,151 shares (Indirect, The Coloma 2021 Irrevocable Trust);
Common Stock — 223,355 shares (Indirect, Coloma Family Trust);
Common Stock — 50,000 shares (Direct)
Footnotes (8)
- F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
- F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.14 to $26.50 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 4 of this Form 4.
- F3. These securities are directly held by The Coloma 2021 Irrevocable Trust, for which the reporting person and his spouse serve as co-trustees.
- F4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.13 to $26.555 per share, inclusive.
- F5. These securities are directly held by the Coloma Family Trust, for which the reporting person and his spouse serve as co-trustees.
- F6. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
- F7. The award vested or vests as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date.
- F8. These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.
Key Figures
RSUs settled into common stock: 50,000 units/shares
Shares sold by The Coloma 2021 Irrevocable Trust: 2,593 shares
Shares sold by Coloma Family Trust: 31,908 shares
+4 more
7 metrics
RSUs settled into common stock
50,000 units/shares
Restricted stock units converting into common stock on September 1, 2026
Shares sold by The Coloma 2021 Irrevocable Trust
2,593 shares
Open-market or private sales on September 1, 2026 at a weighted average of $26.307 per share
Shares sold by Coloma Family Trust
31,908 shares
Open-market or private sales on September 1, 2026 at a weighted average of $26.2876 per share
Total shares sold
34,501 shares
Combined sales by two trusts associated with the reporting person
Post-transaction holdings – Coloma Family Trust
223,355 shares
Indirect ownership after September 1, 2026 sales
Post-transaction holdings – The Coloma 2021 Irrevocable Trust
18,151 shares
Indirect ownership after September 1, 2026 sales
Direct holdings from RSU settlement
50,000 shares
Common stock held directly by the reporting person after RSU conversion
Key Terms
Rule 10b5-1 trading plan, restricted stock unit, weighted average price, irrevocable trust
4 terms
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock unit financial
"Each restricted stock unit represents a contingent right to receive one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
weighted average price financial
"The reported price in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
irrevocable trust financial
"These securities are directly held by The Coloma 2021 Irrevocable Trust"
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
FAQ
What insider transactions did MAZE’s CEO report on September 1, 2026?
Jason V. Coloma reported settlement of 50,000 restricted stock units into common stock and sales totaling 34,501 shares of Maze Therapeutics common stock by trusts associated with him on September 1, 2026.
What are the terms of the 50,000 MAZE restricted stock units that settled?
Each restricted stock unit represents a right to receive one MAZE common share. The award vests as to 1/2 of the total on September 1, 2026 and September 1, 2027, subject to continued service, and the units do not expire but either vest or are cancelled.
AI-generated analysis. How Rhea-AI works. Not financial advice.
